JP2001515492A - カプサイシンまたはカプサイシンアナログを含有する組成物および局所麻酔 - Google Patents
カプサイシンまたはカプサイシンアナログを含有する組成物および局所麻酔Info
- Publication number
- JP2001515492A JP2001515492A JP53982298A JP53982298A JP2001515492A JP 2001515492 A JP2001515492 A JP 2001515492A JP 53982298 A JP53982298 A JP 53982298A JP 53982298 A JP53982298 A JP 53982298A JP 2001515492 A JP2001515492 A JP 2001515492A
- Authority
- JP
- Japan
- Prior art keywords
- capsaicin
- anesthetic
- pain
- site
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Anesthesiology (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.特定の部位での疼痛からの緩和をその処置の必要な患者において提供する 方法であって、以下: a)カプサイシンの注入に続く興奮期の間に起こる激しい侵害受容器の脱荷電で 生じる疼痛の部位への該カプサイシンの注入に関連する該疼痛を緩和するために 該患者に有効量の麻酔薬を投与する工程、および b)カプサイシンまたはカプサイシンアナログを約0.01重量%と10重量%との間 のカプサイシン濃度を有する投薬量処方で該部位に注入する工程であって、ここ で該投薬量は該部位で疼痛を予防するのに有効である工程、 を包含する、方法。 2.前記カプサイシンの濃度が1重量%と7.5重量%との間である、請求項1 に記載の方法。 3.前記カプサイシンの濃度が約5重量%である、請求項2に記載の方法。 4.前記疼痛が神経損傷または神経障害から生じる、請求項1に記載の方法。 5.前記疼痛が、腱炎、筋肉炎(疾患および/または筋肉の炎症から生じる疼 痛)、または炎症に関連するかまたは損傷によって生じる骨もしくは関節の疼痛 、もしくは退行性疾患、慢性関節リウマチ、および他の関節炎症状に関連する関 節炎から生じる請求項1に記載の方法。 6.前記疼痛が発痛点に関連する、請求項1に記載の方法。 7.前記疼痛が軟部組織における腫瘍由来である、請求項1に記載の方法。 8.前記麻酔薬が近位、領域、体性または神経軸(neuraxial)遮断として投与 される、請求項1に記載の方法。 9.前記麻酔薬が前記部位に直接投与される、請求項1に記載の方法。 10.麻薬性鎮痛薬を前記カプサイシンの刺激効果をさらに阻害するために投 与する工程をさらに含む、請求項1に記載の方法。 11.疼痛を処置するためのキットであって、以下: a)該疼痛を緩和する有効投薬量で、患者における疼痛部位での注入のための薬 学的に受容可能な処方物中のカプサイシンまたはカプサイシンアナログ; b)該カプサイシンの注入の結果として起こる激しい侵害受容器の脱荷電から生 じる該疼痛を緩和する有効量で患者に投与するための薬学的に受容可能なキャリ ア中の麻酔薬;および c)該カプサイシンの注入のための手段 を包含する、キット。 12.前記麻酔薬が局所麻酔薬である、請求項11に記載のキット。 13.前記麻酔薬が一般的な麻酔薬である、請求項11に記載のキット。 14.前記麻酔薬の送達手段をさらに含む請求項11に記載のキットであって 、該麻酔薬が近位、領域、体性、または神経軸遮断を果たすように処方される、 キット。 15.前記麻酔薬およびカプサイシンが一緒に処方される、請求項11に記載 のキット。 16.前記麻酔薬が制御された放出の処方物で提供される、請求項11に記載 のキット。 17.前記麻酔薬が麻薬性麻酔薬である、請求項1に記載の方法。 18.前記カプサイシンアナログがレインシフェラトキシン(reinsiferatoxin )である、請求項1に記載の方法。 19.前記麻酔薬が局所麻酔薬として投与される、請求項1に記載の方法。 20.前記麻酔薬が一般的な麻酔薬として投与される、請求項1に記載の方法 。 21.前記麻酔薬が脊髄遮断として投与される、請求項1に記載の方法。 22.前記麻酔薬が硬膜外遮断として投与される、請求項1に記載の方法。 23.前記麻酔薬が神経遮断として投与される、請求項1に記載の方法。 24.前記麻酔薬が麻薬性麻酔薬である、請求項11に記載のキット。 25.前記カプサイシンアナログがレインシフェラトキシンである請求項11 に記載のキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4069797P | 1997-03-13 | 1997-03-13 | |
US60/040,697 | 1997-03-13 | ||
PCT/US1998/004912 WO1998040070A1 (en) | 1997-03-13 | 1998-03-12 | Compositions containing capsaicin or capsaicin analogues and a local anesthetic |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2001515492A true JP2001515492A (ja) | 2001-09-18 |
Family
ID=21912426
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53982298A Pending JP2001515492A (ja) | 1997-03-13 | 1998-03-12 | カプサイシンまたはカプサイシンアナログを含有する組成物および局所麻酔 |
Country Status (12)
Country | Link |
---|---|
US (1) | US5962532A (ja) |
EP (2) | EP1201241B8 (ja) |
JP (1) | JP2001515492A (ja) |
AT (2) | ATE219674T1 (ja) |
AU (1) | AU720859B2 (ja) |
CA (1) | CA2285203C (ja) |
DE (2) | DE69841907D1 (ja) |
DK (2) | DK1201241T3 (ja) |
ES (2) | ES2179473T5 (ja) |
HK (1) | HK1027759A1 (ja) |
PT (2) | PT1201241E (ja) |
WO (1) | WO1998040070A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006513267A (ja) * | 2002-12-18 | 2006-04-20 | アルゴルクス ファーマスーティカルズ,インク | カプサイシノイドの投与 |
JP2008501717A (ja) * | 2004-06-02 | 2008-01-24 | ニューロジズエックス,インコーポレーテッド | 疼痛処置のためのカプサイシノイド、局所麻酔薬および/または鎮痒薬を含有する処方物 |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6239180B1 (en) * | 1995-11-08 | 2001-05-29 | The Regents Of The University Of California | Transdermal therapeutic device and method with capsaicin and capsaicin analogs |
US6248788B1 (en) | 1996-11-06 | 2001-06-19 | The Regents Of The University Of California | Therapeutic method with capsaicin and capasicin analogs |
DK1014946T3 (da) | 1997-09-18 | 2010-06-28 | Pacira Pharmaceuticals Inc | Liposomale anæstetiske sammensætninger med forsinket frigivelse |
JP4575592B2 (ja) | 1997-11-14 | 2010-11-04 | パシラ ファーマシューティカルズ インコーポレーテッド | 多小胞リポソームの製造 |
SE9800139D0 (sv) * | 1998-01-21 | 1998-01-21 | Astra Ab | New use |
US6790207B2 (en) | 1998-06-04 | 2004-09-14 | Curon Medical, Inc. | Systems and methods for applying a selected treatment agent into contact with tissue to treat disorders of the gastrointestinal tract |
US6802841B2 (en) | 1998-06-04 | 2004-10-12 | Curon Medical, Inc. | Systems and methods for applying a selected treatment agent into contact with tissue to treat sphincter dysfunction |
NZ509186A (en) | 1998-07-17 | 2005-01-28 | Skyepharma Inc | Biodegradable compositions for the controlled release of encapsulated substances |
MXPA03000458A (es) * | 2000-07-20 | 2004-06-02 | Neurogen Corp | Ligandos receptores de capsaicina. |
US20040146590A1 (en) * | 2001-03-22 | 2004-07-29 | Iadarola Michael J | Molecular neurochirurgie for pain control administering locally capsaicin or resinferatoxin |
AU2002322024B2 (en) * | 2001-05-31 | 2008-05-08 | Pacira Pharmaceuticals, Inc. | Encapsulation of nanosuspensions in liposomes and microspheres |
EP1414427A4 (en) * | 2001-08-10 | 2004-08-18 | Synta Pharmaceuticals Corp | KAVALACTONE COMPOSITIONS AND METHODS OF USE |
CA2464528A1 (en) * | 2001-11-02 | 2003-05-15 | Elan Corporation, Plc | Pharmaceutical composition |
RS63204A (en) * | 2002-01-17 | 2006-10-27 | Neurogen Corporation | Substituted quinazolin-4-ylamine analogues as modulators of capsaicin |
WO2004021990A2 (en) * | 2002-09-05 | 2004-03-18 | Neurogesx, Inc. | Compositions and kits for the removal of irritating compounds from bodily surfaces |
US8623412B2 (en) * | 2002-09-23 | 2014-01-07 | Elan Pharma International Limited | Abuse-resistant pharmaceutical compositions |
AU2003301190A1 (en) | 2002-12-18 | 2004-07-14 | Algorx | Administration of capsaicinoids |
WO2004091521A2 (en) | 2003-04-10 | 2004-10-28 | Neurogesx, Inc. | Methods and compositions for administration of trpv1 agonists |
WO2006066419A1 (de) | 2004-12-22 | 2006-06-29 | Mestex Ag | Mischung eines vanilloidrezeptoragonisten mit einer nervenregenerationshemmenden substanz, ihre verwendung für die herstellung eines schmerzmittels und verfahren zur applikation dieses mittels |
JP5775246B2 (ja) | 2004-12-28 | 2015-09-09 | メステックス アクチェンゲゼルシャフトMestex Ag | 関節痛を治療する薬剤を生成するためのレシニフェラトキシン(rtx)の使用方法および前記薬剤を適用する方法 |
ATE549018T1 (de) * | 2004-12-28 | 2012-03-15 | Mestex Ag | Verwendung eines vanilloidrezeptoragonisten zusammen mit einem glycosaminoglycan oder proteoglycan für die herstellung eines mittels zur behandlung von gelenkschmerzen und verfahren zur applikation dieses mittels |
EP1858495A2 (en) * | 2005-02-14 | 2007-11-28 | Neurogesx, Inc. | Device for delivery of trpv1 agonists |
WO2006105481A1 (en) * | 2005-03-30 | 2006-10-05 | Neurogesx, Inc. | Low-concentration capsaicin patch and methods for treating neuropathic pain |
EP1865941B8 (en) * | 2005-04-01 | 2010-12-22 | Neurogesx, Inc. | Oils of capsaicinoids and methods of making and using the same |
US8916611B2 (en) * | 2006-04-28 | 2014-12-23 | Warsaw Orthopedic, Inc. | Pharmaceutical removal of neuronal extensions from a degenerating disc |
US7943666B2 (en) * | 2006-07-24 | 2011-05-17 | Trinity Laboratories, Inc. | Esters of capsaicin for treating pain |
US7645767B2 (en) * | 2006-08-31 | 2010-01-12 | Trinity Laboratories, Inc. | Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy |
KR101572634B1 (ko) | 2008-04-04 | 2015-12-01 | 포사이트 비젼4, 인크. | 통증 관리 및 시력을 위한 치료 장치 |
US8158682B2 (en) * | 2008-09-12 | 2012-04-17 | Vallinex, Inc. | Instillation administration of capsaicinoids for the treatment of pain |
US8987328B2 (en) * | 2008-10-30 | 2015-03-24 | Trinity Laboratories, Inc. | Esters of capsaicinoids as dietary supplements |
EP2427056A4 (en) * | 2009-05-07 | 2012-08-22 | Univ Cincinnati | METHODS FOR PREVENTING ISCHEMIC LESION BY STIMULATION OF PERIPHERAL NICE PERIPHERAL |
WO2011044381A1 (en) * | 2009-10-07 | 2011-04-14 | Inflasoothe, Inc. | Pain relief composition, system and method |
US8591025B1 (en) | 2012-09-11 | 2013-11-26 | Nexisvision, Inc. | Eye covering and refractive correction methods for LASIK and other applications |
EP2490620A4 (en) | 2009-10-23 | 2017-03-22 | Forsight Labs, Llc | Conformable therapeutic shield for vision and pain |
US20130066283A1 (en) | 2009-10-23 | 2013-03-14 | Nexisvision, Inc. | Corneal Denervation for Treatment of Ocular Pain |
ES2647087T3 (es) | 2010-07-27 | 2017-12-19 | Flex Pharma, Inc. | Métodos y composiciones para prevenir y aliviar los calambres musculares y para la recuperación de la irritabilidad neuromuscular y de la fatiga después del ejercicio |
CA2816031A1 (en) | 2010-10-25 | 2012-05-10 | Nexisvision, Inc. | Methods and apparatus to identify eye coverings for vision |
WO2012075337A2 (en) | 2010-12-01 | 2012-06-07 | Spinal Modulation, Inc. | Directed delivery of agents to neural anatomy |
US8678584B2 (en) | 2012-04-20 | 2014-03-25 | Nexisvision, Inc. | Contact lenses for refractive correction |
CA2834295A1 (en) | 2011-04-28 | 2012-11-01 | Nexisvision, Inc. | Eye covering and refractive correction methods and apparatus having improved tear flow, comfort, and/or applicability |
US12044905B2 (en) | 2011-04-28 | 2024-07-23 | Journey1 Inc | Contact lenses for refractive correction |
JP6228540B2 (ja) | 2011-09-09 | 2017-11-08 | ヴィズリ・ヘルス・サイエンスィズ・エルエルシー | Trpv1選択的アゴニストを含む疼痛軽減組成物、ならびにその製造および使用 |
US9211274B2 (en) * | 2012-02-01 | 2015-12-15 | Warsaw Orthopedic, Inc. | TRPV1 compounds in a biodegradable polymer carrier |
US9465233B2 (en) | 2012-04-20 | 2016-10-11 | Nexisvision, Inc. | Bimodular contact lenses |
JP6298810B2 (ja) | 2012-04-20 | 2018-03-20 | ネクシスビジョン リクイデーション トラスト | 屈折矯正のためのコンタクトレンズ |
CA2891218A1 (en) | 2012-11-12 | 2014-05-15 | Api Genesis, Llc | Aqueous based capsaicinoid formulations and methods of manufacture and use |
EP3014345A2 (en) | 2013-06-26 | 2016-05-04 | Nexisvision, Inc. | Contact lenses for refractive correction |
US9956166B2 (en) | 2013-09-18 | 2018-05-01 | Sorrento Therapeutics, Inc. | Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin |
US20150133561A1 (en) | 2013-11-12 | 2015-05-14 | Vizuri Health Sciences Llc | Aqueous based capsaicinoid formulations and methods of manufacture and use |
US9341864B2 (en) | 2013-11-15 | 2016-05-17 | Nexisvision, Inc. | Contact lenses having a reinforcing scaffold |
WO2015116559A1 (en) | 2014-01-29 | 2015-08-06 | Nexisvision, Inc. | Multifocal bimodulus contact lenses |
CA2945818C (en) | 2014-04-15 | 2022-05-03 | Vizuri Health Sciences Llc | Topical compositions comprising a capsaicinoid for pain relief, manufacture and use |
US11634384B2 (en) | 2014-11-25 | 2023-04-25 | Concentric Analgesics, Inc. | Prodrugs of phenolic TRPV1 agonists |
US9359316B1 (en) | 2014-11-25 | 2016-06-07 | Concentric Analgesics, Inc. | Prodrugs of phenolic TRPV1 agonists |
CA3025268A1 (en) | 2016-05-25 | 2017-11-30 | Concentric Analgesics, Inc. | Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia |
US11000490B2 (en) | 2016-11-02 | 2021-05-11 | Centrexion Therapeutics Corporation | Stable aqueous capsaicin injectable formulations and medical uses thereof |
EP3570861A4 (en) | 2017-01-23 | 2020-11-18 | Flex Pharma, Inc. | COMPOSITIONS AND PROCEDURES EFFECTING SPORTING PERFORMANCE |
US20200206166A1 (en) | 2017-07-20 | 2020-07-02 | Centrexion Therapeutics Corporation | Methods and compositions for treatment of pain using capsaicin |
US20210283098A1 (en) * | 2018-07-05 | 2021-09-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods and Compositions for Treating Pain and Itch |
TW202019887A (zh) | 2018-07-27 | 2020-06-01 | 美商同心止痛劑股份有限公司 | 酚系trpv1促效劑之聚乙二醇化前藥 |
WO2020041658A1 (en) | 2018-08-24 | 2020-02-27 | Centrexion Therapeutics Corporation | Capsaicin sequential dosing method for treatment of knee joint pain |
US11254659B1 (en) | 2019-01-18 | 2022-02-22 | Centrexion Therapeutics Corporation | Capsaicinoid prodrug compounds and their use in treating medical conditions |
US11447444B1 (en) | 2019-01-18 | 2022-09-20 | Centrexion Therapeutics Corporation | Capsaicinoid prodrug compounds and their use in treating medical conditions |
US11357727B1 (en) | 2021-01-22 | 2022-06-14 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
US11033495B1 (en) | 2021-01-22 | 2021-06-15 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
US11278494B1 (en) | 2021-01-22 | 2022-03-22 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
CN117883414B (zh) * | 2024-03-18 | 2024-06-21 | 山东第二医科大学 | 一种长效缓释辣椒素微球及其制备方法和应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4313958A (en) * | 1980-10-24 | 1982-02-02 | The Procter & Gamble Company | Method of producing analgesia |
US4424205A (en) † | 1982-03-18 | 1984-01-03 | The Procter & Gamble Company | Hydroxyphenylacetamides having analgesic and anti-irritant activity |
US4681897A (en) * | 1984-01-16 | 1987-07-21 | The Procter & Gamble Company | Pharmaceutical products providing enhanced analgesia |
US4939149A (en) † | 1988-10-24 | 1990-07-03 | The United States Of America As Represented By The Department Of Health And Human Services | Resiniferatoxin and analogues thereof to cause sensory afferent C-fiber and thermoregulatory desensitization |
US4997853A (en) * | 1988-12-02 | 1991-03-05 | Galenpharma, Inc. | Method and compositions utilizing capsaicin as an external analgesic |
US5008289A (en) * | 1988-12-02 | 1991-04-16 | Galenpharma, Inc. | Composition for treating nasal disorders and headaches |
US5188837A (en) * | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
US5762963A (en) * | 1995-06-07 | 1998-06-09 | Emory University | Method and compositions for controlling oral and pharyngeal pain using capsaicinoids |
-
1998
- 1998-03-12 ES ES98911614T patent/ES2179473T5/es not_active Expired - Lifetime
- 1998-03-12 ES ES01204692T patent/ES2350755T3/es not_active Expired - Lifetime
- 1998-03-12 AT AT98911614T patent/ATE219674T1/de active
- 1998-03-12 DK DK01204692.6T patent/DK1201241T3/da active
- 1998-03-12 DE DE69841907T patent/DE69841907D1/de not_active Expired - Lifetime
- 1998-03-12 EP EP01204692A patent/EP1201241B8/en not_active Expired - Lifetime
- 1998-03-12 JP JP53982298A patent/JP2001515492A/ja active Pending
- 1998-03-12 US US09/041,294 patent/US5962532A/en not_active Expired - Lifetime
- 1998-03-12 CA CA002285203A patent/CA2285203C/en not_active Expired - Lifetime
- 1998-03-12 PT PT01204692T patent/PT1201241E/pt unknown
- 1998-03-12 WO PCT/US1998/004912 patent/WO1998040070A1/en active IP Right Grant
- 1998-03-12 DK DK98911614T patent/DK0998288T4/da active
- 1998-03-12 PT PT98911614T patent/PT998288E/pt unknown
- 1998-03-12 AT AT01204692T patent/ATE481970T1/de active
- 1998-03-12 DE DE69806246T patent/DE69806246T3/de not_active Expired - Lifetime
- 1998-03-12 AU AU65532/98A patent/AU720859B2/en not_active Expired
- 1998-03-12 EP EP98911614A patent/EP0998288B2/en not_active Expired - Lifetime
-
2000
- 2000-11-08 HK HK00107078A patent/HK1027759A1/xx not_active IP Right Cessation
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006513267A (ja) * | 2002-12-18 | 2006-04-20 | アルゴルクス ファーマスーティカルズ,インク | カプサイシノイドの投与 |
JP2010280668A (ja) * | 2002-12-18 | 2010-12-16 | Alcion Therapeutics Inc | カプサイシノイドの投与 |
JP2014055141A (ja) * | 2002-12-18 | 2014-03-27 | Alcion Therapeutics Inc | カプサイシノイドの投与 |
JP2016047822A (ja) * | 2002-12-18 | 2016-04-07 | センタクシオン・ワン・インコーポレイテッド | カプサイシノイドの投与 |
JP2008501717A (ja) * | 2004-06-02 | 2008-01-24 | ニューロジズエックス,インコーポレーテッド | 疼痛処置のためのカプサイシノイド、局所麻酔薬および/または鎮痒薬を含有する処方物 |
US8889736B2 (en) | 2004-06-02 | 2014-11-18 | Acorda Therapeutics, Inc. | Formulations for the treatment of pain |
US10576047B2 (en) | 2004-06-02 | 2020-03-03 | Grünenthal GmbH | Formulations for the treatment of pain |
Also Published As
Publication number | Publication date |
---|---|
PT1201241E (pt) | 2010-12-02 |
EP1201241A2 (en) | 2002-05-02 |
DE69806246T2 (de) | 2003-02-06 |
DK1201241T3 (da) | 2010-12-13 |
EP1201241B1 (en) | 2010-09-22 |
EP0998288B1 (en) | 2002-06-26 |
EP1201241B8 (en) | 2010-10-27 |
EP0998288B2 (en) | 2005-08-03 |
ES2350755T3 (es) | 2011-01-26 |
CA2285203C (en) | 2005-07-26 |
EP0998288A1 (en) | 2000-05-10 |
CA2285203A1 (en) | 1998-09-17 |
DE69806246T3 (de) | 2006-05-18 |
HK1027759A1 (en) | 2001-01-23 |
DE69841907D1 (de) | 2010-11-04 |
PT998288E (pt) | 2002-11-29 |
ES2179473T5 (es) | 2006-03-01 |
DE69806246D1 (de) | 2002-08-01 |
WO1998040070A1 (en) | 1998-09-17 |
ATE219674T1 (de) | 2002-07-15 |
DK0998288T4 (da) | 2005-08-22 |
ATE481970T1 (de) | 2010-10-15 |
AU6553298A (en) | 1998-09-29 |
US5962532A (en) | 1999-10-05 |
AU720859B2 (en) | 2000-06-15 |
ES2179473T3 (es) | 2003-01-16 |
DK0998288T3 (da) | 2002-10-14 |
EP1201241A3 (en) | 2004-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001515492A (ja) | カプサイシンまたはカプサイシンアナログを含有する組成物および局所麻酔 | |
Dierking et al. | Effect of pre-vs postoperative inguinal field block on postoperative pain after herniorrhaphy | |
EP1243263B1 (en) | Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain | |
JP6298798B2 (ja) | カプサイシノイドの投与 | |
JP2004521111A (ja) | 局所麻酔薬および使用法 | |
AU2002257680A1 (en) | Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain | |
RU2095060C1 (ru) | Композиция, обладающая аналгетической или противовоспалительной активностью, способ аналгезии или лечения аллергических заболеваний | |
JP4867123B2 (ja) | 神経因性疼痛治療剤および神経因性疼痛のモデル動物 | |
JPH08143449A (ja) | 徐放性局所麻酔用注射剤 | |
EP0236477B1 (en) | Use of 6-methylene-6-desoxy-n-cyclopropylmethyl-14-hydroxydihydronormorphine | |
Schim et al. | Overview of pain management. | |
Sokolović et al. | Peripheral streptomycin/lidocaine injections in the treatment of idiopathic trigeminal neuralgia: a preliminary report | |
Tryba | 6 Prevention of chronic pain syndromes by anaesthetic measures: fact or fiction? | |
JP2001516335A (ja) | 鎮痛を生じるための方法および組成物 | |
RU1803139C (ru) | Способ проводниковой анестезии | |
US20050025743A1 (en) | Method of preventing adhesions wtih ifn-upsilon | |
Apruzzese et al. | Bupivacaine Release from Biopolymeric Depots for the Alleviation of Postoperative Pain | |
Berry | SOME PHARMACOLOGICAL ASPECTS OF SYSTEMICALLY ADMINISTERED LOCAL ANESTHETICS WITH PARTICULAR REFERENCE TO THEIR ANTICONVULSANT ACTIVITY | |
WO2002072016A2 (en) | Method of preventing adhesions with ifn-¿y? |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041018 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20080304 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20080528 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080610 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080908 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081020 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081009 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081121 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081107 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081215 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081210 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091110 |